Abstract:Circulating single-molecule amplification and resequencing technology (cSMART) based on next-generation sequencing is highly sensitive, accurate and quantificational. The purpose of this study is to detect the status of 9 driver genes in Chinese NSCLC patients using cSMART and analyze the associations of gene status, clinical characteristics and prognosis. The tissue or plasma samples of 85 patients diagnosed NSCLC from Hangzhou First People's Hospital were collected. EGFR, KRAS, ALK, ROS1, PIK3CA, c-MET, RET, BRAF and HER2 genes were combined detection using cSMART. The association between gene status and clinical characteristics was analyzed by chi-square test and Fisher's exact. Kaplan-Meier survival curves were plotted for overall survival (OS) and analyzed with the log-rank test. Cox proportional hazards regression was used for multivariate analysis. Amongst 85 NSCLC patients, EGFR mutations were more frequent (57.6%), followed by KRAS mutation (18.8%), ALK mutation (10.6%), ALK fusion (9.4%), MET mutation (9.4%), PI3KCA mutation (8.2%), ROS1 fusion (3.5%), BRAF mutation (1.2%), RET fusion (1.2%) and HER2 mutation was not found. Furthermore, the abundances of gene mutation were relatively low. The EGFR mutation rate was higher in patients with adenocarcinoma histology than in those with squamous carcinoma histology (P=0.03). T790M mutation was more common in patients with a history of TKI treatment (P<0.01) and acquired T790M mutation was often accompanied by the original sensitive mutation (P<0.01). ALK fusion was more easily detected in tissue sample. All 8 MET gene exon14 skippings were found in adenocarcinoma histology and this gene alteration often happened after TKI treatment (P=0.02). OS was significantly improved in the EGFR mutation group compared with the wild group (median 32m vs 19m) (P=0.05). No significant survival difference between KRAS mutation and wild group was found (P>0.05). Among EGFR wild advanced NSCLC patients, the median OS of KRAS mutation group was 13 months while that of wild group was 26 months, but there was no significant difference (P>0.05). Multivariant analyzes showed gender, TKI treatment history and smoking history were independent prognostic factors in NSCLC (P<0.05). EGFR mutation is the most common driver gene in Chinese NSCLC, especially in adenocarcinoma patients, which often occurs in exon 19, 20 and 21 region. Then followed by KRAS mutation, it mostly occurs in exon 2. MET gene exon14 skipping is common in patients with adenocarcinoma or post-TKI treatment, which may be related to TKI resistance. Gender, smoking history and TKI treatment history could be independent prognostic factors in NSCLC.

Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients

Discriminating Association of a Common Telomerase Reverse Transcriptase Promoter Polymorphism with Telomere Parameters in Non-Small Cell Lung Cancer with or Without Epidermal Growth Factor Receptor Mutation.

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Cmet-N375s Germline Mutation is Associated with Poor Prognosis of Melanoma in Chinese Patients

Polymorphisms of Key Chemokine Genes and Survival of Non-Small Cell Lung Cancer in Chinese.

Comparison of the C-Met Gene Amplification Between Primary Tumor and Metastatic Lymph Nodes in Non-Small Cell Lung Cancer.

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study

Comprehensive analysis of <i>MET</i> mutations in NSCLC patients in a real-world setting

Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation and Amplification in 5,008 Patients With Lung Cancer

Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.

Genetic Variants in One‐carbon Metabolism‐related Genes Contribute to NSCLC Prognosis in a Chinese Population

Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data

P3.02-040 Driver Gene Detection in Chinese NSCLC Patients Using Csmart and Prognosis Analysis

The Characteristics of MET Exon 14 Skipping Mutations in Chinese Non-Small Cell Lung Cancer: A Retrospective Analysis.

Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer

Association of mutation profiles with metastasis in patients with non-small cell lung cancer

A Pemetrexed-Based Genetic Study of Chinese Han Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).

Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma

Figure S4 from Detection of MET Polysomy by Next-Generation Sequencing and Its Clinical Relevance for MET Inhibitors

Polymorphisms of EpCAM gene and prognosis for non-small-cell lung cancer in Han Chinese